$ONC · BeOne Medicines Ltd. SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for BeOne Medicines Ltd. ($ONC) from November 5, 2026 through November 5, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$ONC 10-Q — BeOne Medicines Ltd.
BeOne's triple-digit net income growth and 33.8% revenue expansion confirm accelerating commercial momentum in oncology.
$ONC 8-K — BeOne Medicines Ltd.
A 34% revenue beat plus a full-year guidance raise signals accelerating commercial momentum for a $40B oncology leader.